A 2024 scoping review by Karacabeyli and Lacaille found GLP-1 medications inhibit the NF-kB pathway one of the bodys master inflammation switches in RA and psoriasis cell models, even before weight changes
Conflicts of Interest: From the study, several coauthors were Eli Lilly employees, and the sponsor designed and oversaw the trial, conducted site monitoring, data collation, and data analysis, with the last author also an employee of the sponsor
Polly facilitates access to independent licensed providers and partner pharmacies available in all 50 U.S
Ivim Health offers virtual consultations with licensed providers who specialize in personalized GLP-1 therapy, making expert care accessible regardless of your location
Retatrutide is evaluated in laboratory research to study GLP-1, GIP, and glucagon receptor pathway research